

1 Elevated DNA Methylation Gestational Age is Associated with the 2 Risk of Later Bipolar Disorder and Anorexia Nervosa in Twins

3 Christine Søholm Hansen^{1,2,3}, Anna Starnawska^{1,4,9}, Alexander Werner Drong⁵, Shantel Marie Weinsheimer^{1,3}
4 Marie Bækvad-Hansen^{1,2}, Dorte Helenius^{1,3}, Marianne Giørtz Pedersen^{1,6,8}, Carsten Bøcker Pedersen^{1,6,8},
5 Preben Bo Mortensen^{1,6}, Michael Christiansen^{1,2,7}, David Michael Hougaard^{1,2}, Cecilia Lindgren⁵, Thomas
6 Mears Werge^{1,3,*†}, Jonas Bybjerg-Grauholm^{1,2,*†}, Alfonso Buil Demur^{1,3,*}

7 1. The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark

8 2. Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark

9 3. Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark

10 4. Department of Biomedicine - Health, Aarhus University, Aarhus, Denmark

11 5. Big Data Institute, University of Oxford, Oxford, United Kingdom

12 6. National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus
13 University, Aarhus, Denmark

14 7. Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

15 8. Centre for Integrated Register-Based Research, CIRRAU, Aarhus University, Aarhus, Denmark

16 9. Center for Integrative Sequencing, iSEQ, Aarhus Genome Centre, Aarhus University, Denmark

17 *. These authors share senior authorship

18 †. These authors share corresponding authorship

19 Abstract

20 **Background:** Foetal development indicates the risk of later disease, but has only been associated with few
21 psychiatric disorders. An aggregated molecular marker of development - DNA methylation based estimates
22 of gestational age (DNAmGA) adjusted for GA, can be indicative of foetal health and development. Twins
23 have the same chronological GA and monozygotic (MZ) twins share genetic liability. We leveraged this to
24 examine whether DNAmGA in neonates associate with later psychiatric disorder, independent of
25 chronological GA, maternal characteristics, genetic influences, and shared environmental factors.

26 **Method:** We estimated DNAmGA in 260 MZ and 396 dizygotic (DZ) twin pairs, later diagnosed with
27 schizophrenia, bipolar disorder, affective/depressive mood disorder, autism spectrum disorder, attention
28 deficit hyperactivity disorder or anorexia. DNAmGA was tested for association with psychiatric outcome by
29 mean discordant twin differences and by linear mixed model (LMM), adjusting for relatedness and
30 potential confounders.

31 **Results:** We found elevated DNAmGA to associate with anorexia between discordant DZ and MZ twins
32 (0.74 weeks, 95%CI[0.34:1.14] and 0.28 weeks, 95%CI[0.04:0.53], respectively), and with bipolar disorder
33 between discordant MZ twins (0.85 weeks, 95%CI[0.16:1.53]). Elevated DNAmGA associated significantly
34 with both in the LMM analysis (0.56 weeks, 95%CI[0.32:0.83] and 0.89 weeks, 95%CI[0.32:1.51],
35 respectively).

36 **Conclusions:** Elevated DNAmGA is associated with two later onset psychiatric disorders in twins, and thus
37 supports a developmental origin of disease. This association was not confounded by variation in
38 conventional measures of foetal development nor genetic liability. We therefore propose that a novel
39 molecular marker of development, can differentiate between later psychiatric outcome in newborn twins.

40 Keywords

41 Foetal Development, Psychiatry, Bipolar Disorder, Anorexia Nervosa, Mental Health, Developmental Origin

42 of Health and Disease (DOHaD), Gestational Age, Birth Weight, DNA Methylation, Blood, Epigenetic Clock,

43 Biomarker, Twins, Monozygotic, Dizygotic

44

45 Background

46 Gestational development is critical for mental health later in life. In fact, the gestational duration until birth
47 has been associated with mental health, where preterm birth is associated with increased disease risk^{1,2}.
48 Similarly, specific point measures of gestational growth and development, such as birth weight is predictive
49 of both early and later onset mental disorders when normalized for length of gestation³ and psychiatric
50 disease in the family (e.g. genetic correlation)⁴.

51 The latter observation illustrates that proper course of brain development during embryonic life is not only
52 dependent on the length, but also on the quality of gestation, where harmful environmental exposures or
53 genetically programmed disease processes may lead to deviant development⁵. Consistently, gestational
54 exposures to alcohol consumption^{6,7}, tobacco smoking⁸ and stressful events^{9,10} among others all augment
55 risk of mental disorders. Common genetic factors acting during embryonic brain development further
56 predispose to mental disorders, possibly through reprogramming gene expression patterns¹¹ and
57 epigenetics¹².

58 This insight has prompted a search for molecular markers of foetal growth and development that reflect
59 effects of both the environmental exposures *in utero* and the genetic background of the individual. Such
60 molecular markers may potentially have the ability to estimate risk of illness and particularly mental
61 disorders, and inform on early pathophysiological processes leading to mental disorders. Recently one such
62 marker, assessing DNA methylation patterns in circulating cells from whole blood, have been shown to
63 correlate with gestational age at birth, termed DNAmGA¹³, analogous to another methylation-based
64 predictor of chronological age in adults¹⁴. Importantly, the DNAmGA predictor adjusted for gestational age
65 associates with BW and maternal socio-economic status (also a risk factor of adverse mental health
66 outcome in offspring)¹³, as well as maternal depression and child mental health issues¹⁵ and maternal and
67 child health related factors, such as maternal age and 1-min APGAR score¹⁶. This suggests that the DNAmGA

68 estimates captures other aspects of developmental processes and neonatal health, in-casu of growth
69 trajectory, in addition to that of gestational length.

70 In this study, we extend this rationale and examined whether DNAmGA estimated at birth can be applied as
71 a marker of specific mental disorders in childhood and adult life. To eliminate uncertainty associated with
72 clinical estimates of gestational age, we perform these analyses in a psychiatric population-based sample of
73 same sex mono- and dizygotic twins, discordant or concordant for six mental disorders as well as in non-
74 affected twin pairs - leveraging the nationwide Danish Neonatal Screening Biobank and detailed diagnostic
75 hospital register-data from the egalitarian and uniform Danish healthcare system.

76 Material and Methods

77 Sample selection

78 As a part of the Danish neonatal screening effort for congenital disorders, neonatal heel blood is collected
79 on Guthrie Cards and stored in the Danish Neonatal Screening Biobank (DNSB) at -20°C ¹⁷.

80 Same sex twin pairs of unknown zygosity were identified by similar criteria of The Lundbeck Foundation
81 Initiative for Integrative Psychiatric Research (iPSYCH) 2012 cohort¹⁸. In short, selection criteria here were
82 twins chosen among twins born in Denmark May 1, 1981 or later, where both twins in a pair should be alive
83 and resident in Denmark on their 1-year birthday. The twin pairs are born between 1981-2009, where the
84 mother had a Danish social security number, and either one or both of the twins had been diagnosed with
85 schizophrenia (SZ), bipolar disorder (BD), affective/depressive mood disorder (MD) (not including BD),
86 autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) or anorexia (ANO) by the
87 ICD-10-DCR (F20, F30-F31, F32-F39, F84.0/F84.1/F84.5/F84.8/F84.9, F90.0, F50.0, respectively)¹⁸ by 2012. A
88 population-based control group of twin pairs, not diagnosed with any of the six disorders (although
89 psychiatric diagnoses may occur) was further included in the dataset. In total 847 same-sex twin pairs were
90 identified. Some individuals had comorbid diagnoses (see Supplementary Figure S1), and in some pairs
91 twins had different diagnoses (e.g. twin/co-twin comorbidities). In both cases samples were used for
92 analysis in more than one psychiatric disorder.

93 DNA preparation and microarray

94 Genomic DNA extraction from neonatal dried blood spots (neoDBS), created from neonatal heel blood
95 soaked Guthrie Cards stored frozen in the DNSB, has previously been described¹⁹. Briefly, 2×3.2 mm
96 punches of neoDBS were taken for each twin and were used for DNA extraction yielding a sufficient
97 quantity and quality of material (as described by Baekvad-Hansen et al.²⁰) for genotyping and DNA
98 methylation profiling²¹. Genomic DNA was extracted with the use of Extract-N-Amp Blood PCR kit (Sigma-
99 Aldrich, St. Louis, Missouri, USA), without further amplification step for Illumina DNAm Array Protocol.

100 Material for genotyping was whole-genome amplified in triplicates with REPLI-g (Qiagen, Hilden, Germany),
101 and analysed according to manufacturer's instructions using the Infinium PsychChip Array (Illumina, San
102 Diego, California, United States). For DNAm array, genomic DNA was bisulfite-converted using the EZ-96
103 DNA Methylation Kit (Zymo Research, Irvine, California, USA) according to the manufacturer's instructions.
104 DNA methylation from the bisulfite-converted DNA was measured using the Infinium
105 HumanMethylation450-BeadChip (450k) or the Infinium HumanMethylationEPIC-BeadChip (EPIC) (see
106 Supplementary Table S1) array (Illumina, San Diego, California, United States) with 7 μ L of bisulfite
107 converted genomic DNA, but otherwise according to the manufacturer's instructions²².

108 Data pre-processing and QC

109 All genetic data was loaded from IDAT intensity files from scanned arrays on iScan (Illumina, San Diego,
110 California, United States). Genotyped SNPs were filtered for $MAF > 0.05$ and $CR > 0.97$. Zygosity of all twin
111 pairs was determined with PLINK v1.07 by Identity by Descent clustering (MZ: $PI-hat \geq 0.9$, and DZ: $0.3 \leq PI-$
112 $hat \leq 0.7$, for $MAF > 0.05$ variants). This identified 524 same-sex DZ and 323 MZ twin pairs.

113 Twins were analysed in pairs in two batches (see Supplementary Table S1) on Illumina 450k Array (MZ twins
114 only) or Illumina EPIC Array (MZ, DZ and unaffected twins). Space restriction caused us to not include 53 DZ
115 pairs on DNAm array and these are not used in the subsequent analysis.

116 DNAm Array IDAT files of 450k and EPIC arrays were loaded separately as red/green intensity datasets
117 (rgSets), with the R-package *Minfi* version 1.24.0²³. 463 DZ and 321 MZ pairs had sufficient quality (Sample
118 call Rate > 0.95 for probe detection P -value < 0.01 and bead count ≥ 3). The rgSets were merged into one
119 combined 450k annotated rgSet, non-shared probes between the two arrays set to missing values and low
120 quality probes (probe call frequency < 0.95 , for probe detection P -value < 0.01 and bead count ≥ 3) were
121 also set to missing values.

122 Sample filtering

123 Registry data on GA and BW were obtained from the National Birth Registry, while sampling day was
124 obtained from the DNSB PKU registry. Z-scores of BW for GA were calculated for males and females
125 separately, with the adjustable foetal weight standard for twins published by Zhang et al.²⁴.

126 Twin pairs were excluded from the study if their blood samples had not been taken on the same day and/or
127 were taken more than 10 days after birth. Samples with insufficient information on BW, GA or lacking
128 verification of individual twin identity within the twin pair were also removed from the study.

129 After QC and sample filtering 396 same-sex DZ and 260 MZ psychiatric pairs, and 49 same sex DZ and 29 MZ
130 unaffected pairs remained for the analysis (totalling 445 DZ and 289 MZ pairs), as shown in Table 1.

131 DNAm-based estimates

132 *Knight DNAm GA estimation*

133 DNAmGA estimation was carried out as described by Knight et al.¹³ using the method available on GitHub
134 (<https://github.com/akknight/PredictGestationalAge>). Beta values were BMIQ normalized, as optional in
135 the source code, and the 148 CpGs needed for estimation were extracted. 6 of the 148 CpG probes
136 required for the estimator were not indigenous to the EPIC array and thus contained missing values for all
137 samples on both arrays (cg02941816, cg19564877, cg20394284, cg25306927, cg25374854, cg26656135).

138 The analysis was consequently performed on only the 142 CpGs, unless otherwise specified (e.g. in the
139 verification shown in Supplementary Figure S2) as suggested in an application note by the authors (see
140 <https://github.com/akknight/PredictGestationalAge>). As DNAmGA is largely confounded by GA, we
141 illustrate associations with DNAmGA as DNAmGA Residuals that are linearly adjusted for GA with sample
142 day after birth.

143

144 *Blood Cell Proportion estimates*

145 Blood cell composition (BCC) in the neonatal blood samples were estimated with the Houseman method for
146 DNAm array data, with the neonatal cord blood reference panel from Bakulski et al.^{25,26}. We normalized
147 the reference panel with our DNAm data by the normal-exponential out-of-band (noob) dye bias correction
148 on the rgSet, to correct for background dye bias between datasets (the Bakulski reference panel and our
149 data). Cellular heterogeneity estimates were obtained for B-cells, CD4 T-cells, CD8 T-cells, granulocytes,
150 monocytes, and nucleated red blood cells (Bcells, CD4T, CD8T, Gran, Mono and nRBC, respectively). We did
151 not estimate natural killer cells in the final iteration of our analysis, since in the preliminary analysis this
152 mostly estimated to zero.

153 *Statistics*

154 All statistical analysis was performed with R Version 3.4.2.

155 *Multiple Testing*

156 Tests significance values were corrected for multiple testing bias by applying False Discovery Rate (FDR)
157 correction, and significant p-values were achieved at FDR corrected $\alpha < 0.05$.

158 *Twin-based heritability and Empirical Bootstrap of Confidence Intervals*

159 We performed 10,000 permutation empirical bootstrapping of the within pair DNAmGA correlation for MZ
160 and DZ twins, and calculated the H^2 by $(r(MZ) - r(DZ))^2$ for each iteration. 95% CI was determined as the
161 lowest 2.5% value and 97.5% values of the 10,000 permutations.

162 *Discordant Twin Model*

163 For each psychiatric diagnosis group (as shown in Table 1) we kept only discordant twin pairs and
164 subtracted DNAmGA of the unaffected twin from the affected twin. The differences were tested with a
165 Student's T-test of means, with the null hypothesis mean=0, with 95% Confidence interval and p-values.

166 *Linear Mixed Model*

167 We applied linear mixed models (LMM) with restricted maximum likelihood (REML), with the R-package
168 lme4²⁷. This controls for the twin relatedness (pair and zygosity) in the dataset and linearly associates
169 DNAmGA and each psychiatric disorder. We included the twin pair identifier and zygosity as random
170 effects, with intercept varying among zygosity and pair identifier within zygosity as: $(1|zygosity/Pair\ ID)$.
171 We further included the array type (450k/EPIC) as a separate random effect for analysis potentially affected
172 by batch (DNAm array data), accounting for potential the batch effects between the 450k and EPIC array,
173 as: $(1|ArrayType)$. In the LMMs we also included potential confounders as covariates – GA, BW for GA,
174 blood cell proportions (common confounder of the heterogeneous blood methylome), birth year, sex and
175 comorbid diagnosis.

176 *Permutation Testing for small N*

177 Based on the con/discordant, MZ/DZ twin study design within each diagnosis group we randomly assigned
178 case/control (1/0) status to randomly sampled MZ/DZ psychiatric samples in pairs. We performed 10,000
179 permutations of each diagnosis group case/control design, as previously described with random effects
180 controlling for relatedness and batch and all covariates. Permuted p-values were obtained as the
181 proportion of permuted p-values smaller than the obtained p-value of the LMM test described above (area
182 under the curve), with the R function *ecdf* (*stats* package).

183 **Results**

184 **The cohort**

185 We identified 260 monozygotic (MZ) and 396 same-sex dizygotic (DZ) twin pairs that were dis- or
186 concordant for at least one of the six psychiatric diagnoses (SZ, BD, MD, ASD, ADHD, and ANO) by latest
187 2012, and also included 29 MZ and 49 DZ unaffected twin pairs into our analysis after filtering and quality
188 control (Table 1). A summary of the cohort is given in Table 1, and the occurrence of comorbid diagnoses

189 are illustrated in Supplementary Figure S1. As expected, the twins were born mildly preterm (median of 37
190 weeks), of which 38% were born prematurely before week 37.

191 [SET IN TABLE 1 HERE]

192 Size mediates risk of later ASD and ADHD

193 First, we used a linear mixed model to associate BW-for-GA with each psychiatric disorder. As shown in
194 Table 1, BW-for-GA was significantly lower in the affected compared to the unaffected twins for ASD or
195 ADHD. For ASD it appeared that unaffected co-twins had higher BW-for-GA than the population mean (Z-
196 score of 0), while affected twins were simultaneously smaller.

197 DNAm-based estimates of gestational age

198 Second, we estimated DNAmGA with the method developed by Knight et al.¹³ and found these to correlate
199 with clinical gestational age plus sample day after birth ($r=0.79$, $N=1468$, $p\text{-value}<2e-16$; Supplementary
200 Figure S3a). DNAmGA correlates within twin pairs ($r=0.82$), and correlation was higher between MZ twins
201 than DZ twins ($r_{MZ}=0.88$ and $r_{DZ}=0.79$; Supplementary Figure S3b). Additionally we found DNAmGA
202 adjusted for GA to correlate between both MZ and DZ twins ($r_{MZ}=0.65$ and $r_{DZ}=0.45$; Supplementary
203 Figure S3c).

204 DNAmGA differences between discordant twins are associated with BD and ANO

205 Next, we calculated the differences in DNAmGA between discordant twin pairs ($\Delta\text{DNAmGA} = \text{DNAmGA}_{\text{aff}} -$
206 $\text{DNAmGA}_{\text{unaff}}$) and found it to be larger than zero in both MZ and DZ twin pairs discordant for ANO (0.28
207 weeks, 95%CI [0.04 : 0.53], and 0.74 weeks, 95%CI [0.34 : 1.14], respectively), and in MZ twins pairs
208 discordant for BD (0.85 weeks, 95%CI [0.16 : 1.53]). In combined analysis of MZ and DZ twin pairs, only ANO
209 significantly associated with ΔDNAmGA (0.48 weeks, 95%CI [0.26 : 0.70]). After FDR correction for multiple
210 testing, only ANO remained significantly associated with ΔDNAmGA ($P_{\text{FDR}} = 3.5e-4$, see Table 2 and Figure 1,

211 for all analyses). There was no overlap between ANO and BD diagnoses in the two diagnostic groups
212 (Supplementary Figure S1).

213 [SET IN FIGURE 1 and TABLE 2 HERE]

214 Elevated DNAmGA is associated with BD and ANO

215 Finally, to allow for adjustment for potential within- and between-pair confounders, including relatedness,
216 we used a linear mixed model (LMM) approach to analyse DNAmGA in all MZ and DZ pairs, con- and
217 discordant of psychiatric diagnosis in each diagnostic group, as well as unaffected pairs (see Table 3). In this
218 model we adjusted DNAmGA for GA, sample day, BW-for-GA, DNAm based blood cell composition,
219 comorbid diagnoses and twin comorbidity, and for birth year and sex. As shown in Table 3, elevated
220 DNAmGA associated with ANO (0.56 weeks, 95%CI [0.32:0.83], $P_{FDR} = 0.00014$) and with BD (0.89 weeks,
221 95%CI [0.32:1.51], $P_{FDR} = 0.012$) (Figure 2), while it did not associate with any other diagnosis (Table 3). We
222 note that, although BW-for-GA, sex and birth year associate with DNAmGA adjusted for GA (Supplementary
223 Figures S4-6), only adjusting for GA and sample day provided comparable test results (The P-value of this is
224 illustrated in Supplementary Figure S7). To test the accuracy of the asymptotic p-values from the LMM, we
225 performed permutation tests for each diagnostic group, confirming the validity for small sample sizes and
226 case-control ratio (Supplementary Figure S7 and Table 3).

227 [SET IN FIGURE 2 and TABLE 3 HERE]

228 Discussion

229 Here we show that a molecular marker of foetal development (DNAmGA) is associated with at least two
230 later onset psychiatric disorders. This is, to our knowledge, the first demonstration of a developmental
231 origin of BD and ANO, that is independent of gestational duration.

232 We used a blood DNA-methylation-based estimator of GA that also correlates with other birth measures of
233 development and health, e.g. BW and APGAR. While these measures correlate with GA, they are not fully

234 explained by it (e.g. variance in BWforGA), and thus may represent alterations in developmental
235 trajectories that are associated with foetal health. We therefore suggest that DNAmGA adjusted for GA can
236 be interpreted as an accumulative score of multiple physiological processes affecting neonatal health and
237 development. We suggest that DNAmGA can be used as a molecular marker of development, without the
238 shortcomings of conventional surrogate markers, although further studies in large and independent
239 samples are necessary to support this hypothesis.

240 Our findings suggest that early and *in utero* exposures influencing (brain) development may act through the
241 epigenome and regulate gene expression¹², which is also supported by our earlier findings in neonatal
242 blood showing that differential DNAm in genes involved with foetal brain development and neurogenesis is
243 associated with later psychiatric outcome in individuals with 22q11.2 deletion syndrome²⁸.

244 The twin design applied in this study has a number of important advantages as chronological GA is identical
245 for a pair of MZ twins, which eliminates the uncertainty of conventional methods to estimate and correct
246 for clinical GA estimates that rely on e.g. last menstrual period or ultrasound assessed foetal metrics.
247 Moreover, clinical GA estimates are influenced by several maternal characteristics, (i.e. smoking and
248 obesity²⁹) and by genetic factors³⁰. Thus differences in DNAmGA in a twin pair will primarily reflect non-
249 shared environment and stochastic effects for MZ twins, but also has a genetic components in DZ twins – as
250 demonstrated in this study by twin heritability estimates of DNAmGA.

251 We confirmed the results obtained from the simple discordant-twin model in MZ twins, using a Linear
252 Mixed Model that allowed us to adjust for potential confounders, e.g. blood cell composition. This is
253 relevant because it indicates that the methylation differences do not reflect a global confounding by
254 variance in blood cell type heterogeneity.

255 Another study of DNAmGA in children of mothers with antenatal depression demonstrated that decreased
256 DNAmGA was associated with later psychiatric problems³¹. While such studies in singletons are prone to be
257 influenced by underlying genetic and maternal characteristics influencing estimate, as well as uncertainty in

258 measures of chronological GA, we do not expect them to reflect the same pathophysiology as observed in
259 this study of twins.

260 Our study is generally limited by the small sample sizes which hamper the power to detect other possible
261 associations than those for BD and ANO. This emphasizes the need for replication in larger independent
262 cohorts which would benefit from the inclusion of both twins and singletons. The latter acknowledging that
263 twins may not represent the pathophysiology of singletons as they are associated with multiple birth
264 complications, prematurity and lower BW.

265 In conclusion, we show for the first time, that an epigenetic measure of development measured at birth,
266 DNAmGA, is indicative of risk for developing BD and ANO in adulthood. This risk is independent of genetic
267 influences and conventional measures of neonatal development (i.e., GA, BW for GA). Thus, our findings
268 further support a developmental origin of psychiatric disorders.

269 Declarations

270 Ethics approval and consent to participate

271 The Danish Scientific Ethics Committee (approval number 37356) approved this study, as did the Danish

272 Health Data Authority, the Danish Data Protection Agency and the Danish Neonatal Screening Biobank

273 steering committee. Consent is given in the form of passive consent, and relies on protection of personal

274 information and anonymization of all involved personal data and sample material.

275 The manuscript was made available on bioRxiv ahead of publishing.

276 Consent for publication

277 Not applicable

278 Availability of data and material

279 Individual level data can be accessed only through secure servers operated by iPSYCH consortium.

280 Download of individual level information is prohibited due to the sensitive nature of these data. iPSYCH

281 encourage national and international collaboration. For details, please contact the corresponding authors.

282 Competing interests

283 The authors declare that they have no competing interests.

284 Funding

285 This project was funded by the Lundbeck Foundation through “The Lundbeck Foundation Initiative for

286 Integrative Psychiatric Research” (iPSYCH).

287 Authors' contributions

288 CSH carried out all QC and data analysis of methylation, interpretation of results and prepared the

289 manuscript. AS, AWD and SW provided interpretation of methylation analysis in addition AWD provided

290 pre-processing pipeline and AS provided epigenetic psychiatric interpretation. DH provided vital insight into

291 twin analysis and interpretation of results and SH provided interpretation of these from DNA methylation
292 perspective. MABH, DMH and JBG arrayed and selected neoDBS samples from the DNSB (with our lab
293 technician team - see acknowledgements) and provided vital background knowledge and protocol for the
294 work with such material. MC provided vital knowledge of pregnancy, delivery and neonatal health and
295 development in Denmark reflected in the DNSB and provided vital interpretation of the results in this
296 paper. PBM, CBP and MGP provided and curated all psychiatric phenotypes and registry data in the cohort
297 and provided all additional twin relevant information for verification of the pairs. CL provided vital
298 intellectual input on project feasibility, design and the application of DNA methylation in multifactorial
299 disorders. TMW, JBG and AB conceived and designed the study as well as interpreted results and formed
300 conclusions. Specifically AB provided the concept, analysis pipeline and conceived additional supportive
301 analysis in heritability estimates, linear mixed model and interpretation.

302 All authors read and approved the final manuscript.

303 Acknowledgements

304 This research has been conducted using the Danish National Biobank resource, supported by the Novo
305 Nordisk Foundation.

306 Our talented team of technicians: Marie Louise Johannsen, Rikke Holm Agerbo, Mia Egeberg Engwald and
307 Gimel Pucci Infante Jørgensen, without whom this study would not have been feasible in such a large
308 complex cohort, where high data quality from small input amounts is a necessity, and the many twin pairs
309 need to be correctly identified and carefully extracted from the DNSB.

310 This publication would not have been possible without the passionate support and ideas of our dear
311 departed friend and colleague Mads Vilhelm Hollegaard. He envisioned and paved the way for this and
312 many other projects rooted in the DNSB – he is missed immensely.

313

314 References

- 315 1. Cronin, F. M., Segurado, R., McAuliffe, F. M., Kelleher, C. C. & Tremblay, R.
316 E. Gestational age at birth and ‘Body-Mind’ health at 5 years of age: A population
317 based cohort study. *PLoS One* **11**, 151222 (2016).
- 318 2. Nosarti, C. *et al.* Preterm Birth and Psychiatric Disorders in Young Adult Life. *Arch. Gen. Psychiatry*
319 **69**, 610–617 (2012).
- 320 3. Aarnoudse-Moens, C. S. H., Weisglas-Kuperus, N., van Goudoever, J. B. & Oosterlaan, J. Meta-
321 Analysis of Neurobehavioral Outcomes in Very Preterm and/or Very Low Birth Weight Children.
322 *Pediatrics* **124**, 717–728 (2009).
- 323 4. Pettersson, E., Larsson, H., D’Onofrio, B., Almqvist, C. & Lichtenstein, P. Association of Fetal Growth
324 with General and Specific Mental Health Conditions. *JAMA Psychiatry* **76**, 536–543 (2019).
- 325 5. Schlotz, W. & Phillips, D. I. W. Fetal origins of mental health: Evidence and mechanisms. *Brain.*
326 *Behav. Immun.* **23**, 905–916 (2009).
- 327 6. Sayal, K., Heron, J., Golding, J. & Emond, A. Prenatal alcohol exposure and gender differences in
328 childhood mental health problems: A longitudinal population-based study. *Pediatrics* **119**, 2006–
329 1840 (2007).
- 330 7. Fryer, S. L., McGee, C. L., Matt, G. E., Riley, E. P. & Mattson, S. N. Evaluation of psychopathological
331 conditions in children with heavy prenatal alcohol exposure. *Pediatrics* **119**, (2007).
- 332 8. Ashford, J., Van Lier, P. A. C., Timmermans, M., Cuijpers, P. & Koot, H. M. Prenatal smoking and
333 internalizing and externalizing problems in children studied from childhood to late adolescence. *J.*
334 *Am. Acad. Child Adolesc. Psychiatry* **47**, 779–787 (2008).
- 335 9. Khashan, A. S. *et al.* Higher risk of offspring schizophrenia following antenatal maternal exposure to

- 336 severe adverse life events. *Arch. Gen. Psychiatry* **65**, 146–152 (2008).
- 337 10. Bergman, K., Sarkar, P., O'Connor, T. G., Modi, N. & Glover, V. Maternal stress during pregnancy
338 predicts cognitive ability and fearfulness in infancy. *J. Am. Acad. Child Adolesc. Psychiatry* **46**, 1454–
339 1463 (2007).
- 340 11. Schork, A. J. *et al.* A genome-wide association study for shared risk across major psychiatric
341 disorders in a nation-wide birth cohort implicates fetal neurodevelopment as a key mediator.
342 *bioRxiv* 240911 (2017). doi:10.1101/240911
- 343 12. Wadhwa, P. D., Buss, C., Entringer, S. & Swanson, J. M. Developmental origins of health and disease:
344 Brief history of the approach and current focus on epigenetic mechanisms. *Semin. Reprod. Med.* **27**,
345 358–368 (2009).
- 346 13. Knight, A. K. *et al.* An epigenetic clock for gestational age at birth based on blood methylation data.
347 *Genome Biol.* 1–11 (2016). doi:10.1186/s13059-016-1068-z
- 348 14. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, R115 (2013).
- 349 15. Suarez, A. *et al.* *The Epigenetic Clock at Birth: Associations With Maternal Antenatal Depression and*
350 *Child Psychiatric Problems. Journal of the American Academy of Child & Adolescent Psychiatry*
351 *www.jaacap.org* **321**, (Elsevier, 2018).
- 352 16. Girchenko, P. *et al.* Associations between maternal risk factors of adverse pregnancy and birth
353 outcomes and the offspring epigenetic clock of gestational age at birth. *Clin. Epigenetics* **9**, (2017).
- 354 17. Nørgaard-Pedersen, B. & Hougaard, D. M. Storage policies and use of the Danish Newborn Screening
355 Biobank. *J. Inherit. Metab. Dis.* **30**, 530–536 (2007).
- 356 18. Pedersen, C. B. *et al.* The iPSYCH2012 case-cohort sample: New directions for unravelling genetic
357 and environmental architectures of severe mental disorders. *bioRxiv* (2017).

- 358 19. Hollegaard, M. V *et al.* Genome-wide scans using archived neonatal dried blood spot samples. *BMC*
359 *Genomics* **10**, 297 (2009).
- 360 20. Bækvad-Hansen, M. *et al.* Evaluation of whole genome amplified DNA to decrease material
361 expenditure and increase quality. *Mol. Genet. Metab. Reports* **11**, 36–45 (2017).
- 362 21. Hollegaard, M. V. *et al.* Archived neonatal dried blood spot samples can be used for accurate whole
363 genome and exome-targeted next-generation sequencing. *Mol. Genet. Metab.* **110**, 65–72 (2013).
- 364 22. Hollegaard, M. V., Grauholm, J., Nørgaard-Pedersen, B. & Hougaard, D. M. DNA methylome profiling
365 using neonatal dried blood spot samples: A proof-of-principle study. *Mol. Genet. Metab.* **108**, 225–
366 231 (2013).
- 367 23. Aryee, M. J. *et al.* Minfi: A flexible and comprehensive Bioconductor package for the analysis of
368 Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363–1369 (2014).
- 369 24. Zhang, J. *et al.* An adjustable fetal weight standard for twins: a statistical modeling study. *BMC Med.*
370 **13**, 159 (2015).
- 371 25. Houseman, E. A. *et al.* DNA methylation arrays as surrogate measures of cell mixture distribution.
372 *BMC Bioinformatics* **13**, 86 (2012).
- 373 26. Bakulski, K. M. *et al.* DNA methylation of cord blood cell types: Applications for mixed cell birth
374 studies. *Epigenetics* **11**, 354–362 (2016).
- 375 27. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat*
376 *Soft* **67**, 48 (2015).
- 377 28. Starnawska, A. *et al.* Differential DNA methylation at birth associated with mental disorder in
378 individuals with 22q11.2 deletion syndrome. *Transl. Psychiatry* **7**, e1221 (2017).
- 379 29. Thagaard, I. N. *et al.* The effect of obesity on early fetal growth and pregnancy duration: A cohort

380 study. *J. Matern. Neonatal Med.* **31**, 2941–2946 (2018).

381 30. Liu, X. *et al.* Variants in the fetal genome near pro-inflammatory cytokine genes on 2q13 are
382 associated with gestational duration. *bioRxiv* 423897 (2018). doi:10.1101/423897

383 31. Suarez, A. *et al.* The Epigenetic Clock at Birth: Associations With Maternal Antenatal Depression and
384 Child Psychiatric Problems. *J. Am. Acad. Child Adolesc. Psychiatry* **57**, 321-328.e2 (2018).

385

386

Diagnosis Groups (N pairs)	Pairs N		Sex (%male)	Sample Age Years (mean+/-SEM)	GA Weeks (mean+/-SEM)	BW for GA Z-scores	
	DZ (%Con)	MZ (%Con)				Intercept Est+/-Std.Err	Affected d (Est+/-Std.Err)
	SZ (43)	26 (0%)	17 (6%)	46.5%	24.3 +/- 0.63***	36.1 +/- 0.37	-0.07 +/- 0.21
BD (13)	6 (0%)	7 (14%)	15.4%	24.1 +/- 1.1 ***	37.3 +/- 0.55	-0.01 +/- 0.61	-0.06 +/- 0.38
MD (241)	122 (3%)	119 (13%)	27.8%	23.2 +/- 0.3 ***	37.2 +/- 0.13	-0.12 +/- 0.10	0.02 +/- 0.08
ASD (215)	152 (3%)	63 (40%)	73.0%	15.1 +/- 0.36	36.5 +/- 0.16	0.29 +/- 0.09**	-0.23 +/- 0.09*
ADHD (211)	144 (11%)	67 (19%)	78.7%	15.7 +/- 0.39	36.1 +/- 0.17	0.02 +/- 0.10	-0.28 +/- 0.10*
ANO (63)	26 (0%)	37 (8%)	11.1%	20.7 +/- 0.61***	36.3 +/- 0.32	0.17 +/- 0.16	-0.07 +/- 0.16
Unaffected (78)	49	29	50.0%	15.7 +/- 0.73	36.6 +/- 0.24	0.05 +/- 0.10	-

387 **Table 1: Sample overview for each psychiatric diagnosis group and unaffected twin pairs.** Table shows samples size
388 in pairs (N), concordance rate (%Con), sex distribution (%male), mean sample age (at data extraction 2012) and mean
389 gestational age (GA). Differences between each diagnosis group (SZ, BD, MD, ASD, ADHD or ANO) and unaffected pairs
390 were assessed by Welch Two-Sample T-Test (null hypothesis is equal means) for sample age and GA. Samples in
391 diagnosis groups SZ, BD, MD and ANO were older than unaffected when analysed in 2012 (synonymous with earlier
392 birth years), while no significant differences in GA was observed between psychiatric and unaffected samples. BW
393 adjusted for GA (BW for GA) in Z-scores was tested with a LMM controlling for twin pair and zygosity. The "Intercept"
394 column is the estimate of the mean BW for GA of the unaffected co-twins in the affected pairs, while the estimate of
395 the difference in BW for GA of the affected twins from the unaffected is given in the "Affected" column. Statistical
396 significance is indicated after multiple testing correction with false discovery rate correction (FDR) with FDR alpha:
397 * <0.05 , ** <0.01 or *** <0.001 .

398

399

Diagnosis	MZ Discordant Pairs			DZ Discordant Pairs			All Discordant Pairs		
	N Pairs	Mean [95% CI]	P-Value (FDR)	N Pairs	Mean [95% CI]	P-Value (FDR)	N Pairs	Mean [95% CI]	P-Value (FDR)
SZ	16	-0.20 [-0.56 : 0.16]	0.25 (0.51)	26	0.21 [-0.26 : 0.67]	0.38 (0.56)	42	0.05 [-0.27 : 0.37]	0.75 (0.75)
BD	6	0.85 [0.16 : 1.53]	0.03 (0.08)	6	0.20 [-0.91 : 1.30]	0.67 (0.67)	12	0.52 [-0.05 : 1.09]	0.07 (0.21)
MD	104	0.01 [-0.18 : 0.15]	0.88 (0.94)	118	-0.05 [-0.26 : 0.16]	0.64 (0.67)	222	0.03 [-0.17 : 0.10]	0.64 (0.75)
ASD	38	0.09 [-0.17 : 0.35]	0.50 (0.74)	147	-0.08 [-0.27 : 0.10]	0.37 (0.56)	185	-0.05 [-0.20 : 0.11]	0.54 (0.75)
ADHD	54	0.01 [-0.27 : 0.25]	0.94 (0.94)	128	0.12 [-0.08 : 0.33]	0.24 (0.56)	182	0.08 [-0.08 : 0.24]	0.31 (0.62)
ANO	34	0.28 [0.04 : 0.53]	0.03 (0.08)	26	0.74 [0.34 : 1.14]	7.7e-4 (4.6e-3)	60	0.48 [0.26 : 0.70]	5.8e-5 (3.5e-4)

400 **Table 2: DNAmGA difference of discordant pairs:** The table shows the DNAmGA mean difference within discordant
 401 pairs for each psychiatric diagnosis (affected – unaffected). Positive values indicate higher DNAmGA in the affected
 402 twin relative to the unaffected. This was tested in only MZ pairs, only DZ pairs and in all discordant pairs (MZ and DZ),
 403 with One Sample T-Tests of means (null hypothesis is mean=0). Statistical significance was obtained at FDR<0.05.
 404 Cursive-bold writing indicates marginal associations that were not significant after FDR correction while bold writing
 405 indicates significant association after FDR correction.

406

407 **Figure 1: Boxplots of DNAmGA difference in psychiatric discordant pairs.** Boxplot shows distribution of DNAmGA
408 differences (affected – unaffected) within psychiatric discordant pairs for each psychiatric diagnosis. Differences within
409 DZ pairs are illustrated with gray boxes while differences within MZ pairs are illustrated with white boxes. The sample
410 size is given for each box as N pairs and difference between each twin pair is illustrated with black jittered dots. Dashed
411 line marks a difference of 0, and dots above the line are interpreted as elevated DNAmGA in the affected twin over the
412 unaffected co-twin. Test P-values from One-Sample T-Test (null hypothesis is mean=0) are illustrated as (*<0.1,
413 *<0.05, **<0.01, after FDR correction for multiple testing.

414 **Figure 2: Increased DNAmGA adjusted for within and between pair covariates (shown as residuals) associates with**
415 **later BD and ANO.** Boxplots shows DNAmGA adjusted for GA, sample day, sex, birth year, BW for GA and blood cell
416 composition as residuals association with each psychiatric disorder. Unaffected (white box) and affected (gray box)
417 samples of each disorder are illustrated as jittered dots. Dashed line marks DNAmGA residuals=0. LMM FDR corrected
418 p-values are illustrated as *<0.05, **<0.01, ***<0.001.


419

Diagnosis Group	Affected (N samples)	Unaffected (N samples)	Comorbid Diagnoses (in twin/co-twin)	Est (weeks) [95%CI]	LMM p-value / (FDR) / [PermP.]
SZ	44	198	BD, MD, ASD, ADHD, ANO	-0.13 [-0.52:0.27]	0.52 (0.77) [0.53]
BD	14	168	SZ, ADHD	0.89 [0.32:1.51]	0.004 (0.012) [0.0035]
MD	260	378	SZ, ASD, ADHD, ANO	0.02 [-0.12:0.16]	0.81 (0.81) [0.81]
ASD	245	341	SZ, MD, ADHD, ANO	-0.02 [-0.17:0.13]	0.76 (0.81) [0.77]
ADHD	240	338	SZ, BD, MD, ASD	0.09 [-0.07:0.25]	0.27 (0.54) [0.26]
ANO	66	216	SZ, MD, ASD	0.56 [0.32:0.83]	0.000024 (0.00014) [<1e-4]


420 **Table 3: Summarized results from LMMs of DNAmGA association with psychiatric diagnosis adjusted for Comorbid**
421 **diagnosis, GA, sample day, sex, birth year, BW for GA and blood cell composition).** Table summarizes the number of
422 affected and unaffected samples (N) analysed in each model. Unaffected samples included 156 unaffected samples
423 from the unaffected pairs. Comorbid diagnosis of affected twin or of the co-twin were included as covariates in the
424 LMM and are listed for each model. Covariates included in all LMMs were BW for GA, blood cell composition, GA,
425 sample day, birth year and sex, and we adjusted for twin pair, zygosity and array type with random effects. LMM
426 estimates with 95% CI of DNAmGA effect size in weeks, P-value (with FDR correction for multiple testing and permuted
427 p-values) are listed for each diagnosis. Statistical significance was obtained at FDR<0.05. Bold writing indicates
428 significant association after FDR correction. Significance was confirmed by permuted p-values.

429


SZ Discordant Pairs




BD Discordant Pairs




MD Discordant Pairs




ASD Discordant Pairs




ADHD Discordant Pairs




ANO Discordant Pairs




Schizophrenia




Bipolar Disorder




Affective/Depressive Mood Disorder



Autism Spectrum Disorder



Attention Deficiet Hyperactivity Disorder



Anorexia Nervosa

